Therapy News and Research

RSS

Proton therapy offers life-changing benefits to children with cancer

The Children's Hospital of Philadelphia announces the availability of proton therapy, a precise form of cancer radiation that offers potentially life-changing benefits to children with brain tumors and other solid tumors. The Hospital's Cancer Center has recently begun using proton treatment at the new Roberts Proton Therapy Center, a cutting-edge radiation oncology facility located across the street from Children's Hospital in Penn Medicine's Perelman Center for Advanced Medicine.

2 Jun 2010

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

FDA grants priority review status to Eisai's eribulin NDA

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

2 Jun 2010

Parents can play critical role in children's autism treatment: New research

New research on behavioral treatment for autism has been released by the Chicago Children's Clinic, advancing previous findings that parents can play a critical role in a child's autism treatment.

2 Jun 2010

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Cancer patients who've been told to rest and avoid exercise can - and should - find ways to be physically active both during and after treatment, according to new national guidelines. Kathryn Schmitz, PhD, MPH, an associate professor of Epidemiology and Biostatistics and a member of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, will present these guidelines at an educational session at the 2010 meeting of the American Society of Clinical Oncology, aimed at making cancer exercise rehabilitation programs as common as those offered to people who have had heart attacks or undergone cardiac surgery.

2 Jun 2010

Scientists discover key mechanism of cancer cells

Many tumor cells would not be viable due to aberrant chromosome distribution if they had not developed a special trick. Scientists from the German Cancer Research Center have investigated which genes are responsible for this survival strategy of cancer cells.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

FDA approves Prolia for postmenopausal women with osteoporosis

The U.S. Food and Drug Administration approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

AAPA recognizes role of PAs in transforming health care delivery with 2010 PAragon Awards

The American Academy of Physician Assistants celebrated the role of physician assistants in transforming health care delivery at its 38th Annual Physician Assistant Conference in Atlanta yesterday with its presentation of the 2010 PAragon Awards.

1 Jun 2010

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

EpiCept Corporation today provided an update on the post-approval commitments requested by the European Medicines Agency as part of its marketing authorization for Ceplene (histamine dihydrochloride). Ceplene is approved in the EU for remission maintenance and prevention of relapse in adults with Acute Myeloid Leukemia in first complete remission.

1 Jun 2010

Elekta acquires Resonant Medical

Elekta today announced the acquisition of Resonant Medical Inc., Montreal Canada. Through this acquisition, Elekta adds exciting new solutions for image guidance as well as highly skilled R&D resources in the field of oncology imaging and motion management.

From Elekta 1 Jun 2010

New study finds usage of antidepressants increases risk of miscarriage in pregnant women

A new study in CMAJ (Canadian Medical Association Journal) found a 68% increase in the overall risk of miscarriage in pregnant women using antidepressants.

1 Jun 2010

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Results of a subanalysis from the FAIR-HF study demonstrate that correcting iron deficiency with Ferinject (ferric carboxymaltose) can improve renal function in chronic heart failure patients. Ferinject is an intravenous iron product used to treat iron deficiency and iron deficiency anaemia.

From CSL Ltd 31 May 2010

Health Robotics South East Asia opens two outsourcing centers in Kuala Lumpur and Bangkok

Health Robotics today announced that its joint venture Health Robotics South East Asia Ltd. scored two strategic wins by reaching agreements on two separate government-sponsored projects to deliver CytoCare-made accurate and sterile oncology patient doses in Kuala Lumpur and Bangkok, respectively.

31 May 2010

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

31 May 2010

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs. This finding may help identify other transplant recipients who could safely reduce or end use of immunosuppressive therapy. In 2008, more than 80,000 people in the United States were living with a kidney transplant.

31 May 2010

Therapy News and Research

Proton therapy offers life-changing benefits to children with cancer

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

FDA grants priority review status to Eisai's eribulin NDA

Parents can play critical role in children's autism treatment: New research

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Scientists discover key mechanism of cancer cells

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

FDA approves Prolia for postmenopausal women with osteoporosis

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

New technique transforms iPS cells into natural tumor killers

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

AAPA recognizes role of PAs in transforming health care delivery with 2010 PAragon Awards

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

Elekta acquires Resonant Medical

New study finds usage of antidepressants increases risk of miscarriage in pregnant women

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Health Robotics South East Asia opens two outsourcing centers in Kuala Lumpur and Bangkok

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News